Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease
Anavex Life Sciences Corp. (AVXL)
NASDAQ:AMEX Investor Relations:
anavex.com/share-data
Company Research
Source: GlobeNewswire
Findings underpin the scientific rationale for Anavex’s targeted autophagy approach with orally administered blarcamesine Convergence of impaired autophagy and synaptic dysfunction across neurodevelopmental and neurodegenerative conditions aligns with blarcamesine’s mechanism of action These findings support Anavex’s intent to advance blarcamesine into pivotal clinical studies to further evaluate its potential in addressing unexpectedly common CNS disease mechanisms NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced new findings on the shared biology between autism spectrum disorder (ASD) and Alzheimer’s disease (AD), a core
Show less
Read more
Impact Snapshot
Event Time:
AVXL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVXL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVXL alerts
High impacting Anavex Life Sciences Corp. news events
Weekly update
A roundup of the hottest topics
AVXL
News
- Anavex Life Sciences Teases New Pivotal Blarcamesine Trials, Maps Regulatory Path at Needham Conference [Yahoo! Finance]Yahoo! Finance
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Anavex Life Sciences (AVXL) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.MarketBeat
- Anavex Life Sciences Provides Comprehensive Regulatory Update [Yahoo! Finance]Yahoo! Finance
- Anavex Life Sciences Provides Comprehensive Regulatory UpdateGlobeNewswire
AVXL
Earnings
- 2/9/26 - Beat
AVXL
Analyst Actions
- 2/10/26 - HC Wainwright
AVXL
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/25/26 - Form 8-K
- 2/25/26 - Form 8-K
- AVXL's page on the SEC website